Lakefront Biotherapeutics (GXE)
Summary
GXE Chart
Lakefront Biotherapeutics (GXE) FAQ
What is the stock price today?
On which exchange is it traded?
What is its stock symbol?
Does it pay dividends? What is the current yield?
What is its market cap?
Has Lakefront Biotherapeutics ever had a stock split?
Lakefront Biotherapeutics Profile
| Biotechnology Industry | Healthcare Sector | Henry Gosebruch CEO | XDUS Exchange | - ISIN |
| BE Country | 704 Employees | - Last Dividend | - Last Split | - IPO Date |
Overview
Galapagos NV represents a dynamic force in the pharmaceutical landscape, focusing its efforts on the development of innovative medicines within the realms of oncology and immunology. A biotechnology entity with a broad geographic footprint, its operations span across the United States and Europe, signifying its prominence on the global stage. Established in 1999 and with its headquarters positioned in Mechelen, Belgium, Galapagos NV exemplifies a commitment to addressing complex health issues through groundbreaking scientific research and development. The company’s strategic collaborations with esteemed partners such as Gilead Sciences, Inc. and AbbVie S.à r.l. further amplify its capabilities and reach in pursuing advanced therapeutic solutions.
Products and Services
Galapagos NV's product pipeline is a testament to its innovation and strategic focus in the field of biotechnology, specifically within oncology and immunology:
- GLPG3667 - This candidate has successfully completed a phase 1b trial. It exhibits the company's dedication to advancing treatment options that the scientific community and patients eagerly await.
- GLPG5101 - Representing a significant stride in cancer treatment, GLPG5101 is a CD19 CAR-T product candidate. Currently being evaluated in a Phase 1/2 trial for relapsed/refractory non-Hodgkin lymphoma, this therapy is manufactured at the point-of-care, highlighting Galapagos NV’s commitment to delivering personalized and effective treatments.
- GLPG5201 - Similar in its manufacturing process to GLPG5101, this CD19 CAR-T product candidate targets a different, yet equally challenging, arena: relapsed/refractory chronic lymphocytic leukemia. Currently in phase 1/2 trials, GLPG5201 underscores Galapagos NV’s pursuits in harnessing CAR-T cell therapies for complex leukemia treatments.
- GLPG5301 - Taking aim at relapsed/refractory multiple myeloma, GLPG5301 is a BCMA CAR-T product candidate, also currently in phase 1/2. Manufactured at the point-of-care, it represents the cutting edge of treatment strategies for a particularly challenging form of cancer, demonstrating Galapagos NV’s innovative approach to therapeutic development.
